Dynavax Technologies Co. (NASDAQ:DVAX) – Equities research analysts at William Blair decreased their FY2020 earnings per share estimates for Dynavax Technologies in a research report issued to clients and investors on Tuesday, December 3rd. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings of ($1.10) per share for the year, down from their prior estimate of ($1.09). William Blair currently has a “Buy” rating on the stock. William Blair also issued estimates for Dynavax Technologies’ Q4 2020 earnings at ($0.25) EPS, FY2021 earnings at ($0.68) EPS, FY2022 earnings at ($0.51) EPS and FY2023 earnings at ($0.30) EPS.
DVAX has been the topic of several other research reports. BidaskClub upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Zacks Investment Research raised Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, HC Wainwright restated a “buy” rating on shares of Dynavax Technologies in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Dynavax Technologies currently has a consensus rating of “Buy” and an average price target of $12.63.
Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.10). Dynavax Technologies had a negative return on equity of 399.60% and a negative net margin of 519.95%. The company had revenue of $10.58 million during the quarter, compared to the consensus estimate of $10.31 million. During the same period in the prior year, the firm posted ($0.65) EPS. The business’s revenue was up 624.7% on a year-over-year basis.
Large investors have recently modified their holdings of the business. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Dynavax Technologies by 95.0% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,984 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 3,402 shares during the period. Bank of Montreal Can increased its position in shares of Dynavax Technologies by 148.4% during the second quarter. Bank of Montreal Can now owns 7,440 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 4,445 shares during the period. Wedbush Securities Inc. bought a new stake in shares of Dynavax Technologies during the second quarter valued at about $42,000. Ingalls & Snyder LLC purchased a new stake in shares of Dynavax Technologies in the third quarter worth about $52,000. Finally, M&T Bank Corp lifted its holdings in shares of Dynavax Technologies by 29.5% in the second quarter. M&T Bank Corp now owns 13,685 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 3,116 shares in the last quarter. Hedge funds and other institutional investors own 82.36% of the company’s stock.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
See Also: What is the Nikkei 225 index?
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.